首页 › 基金 › BRAIDWELL LP › NVCT
BRAIDWELL LP 对 NVCT 的持仓历史
NUVECTIS PHARMA INC · 医疗保健
BRAIDWELL LP 在 Q3 2026 的 13F 申报中披露持有 NVCT(NUVECTIS PHARMA INC)1,573,823 股,市值约 US$33.2M,约占其申报组合的 1.46%,在其申报持仓中市值排名第 24 位。 BRAIDWELL LP 于 Q3 2026 首次申报该持仓。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
BRAIDWELL LP 对 NVCT 的持仓演变
BRAIDWELL LP 于 Q3 2026 首次披露 NVCT 持仓:1,573,823 股(约 US$33.2M)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2026 | 1.57M | $33.24M | 新进 |
关于 NVCT 与 13F 数据
NVCT(NUVECTIS PHARMA INC)属于医疗保健行业。我们追踪的基金中还有 62 只申报持有 NVCT,申报仓位最大的包括:Soleus Capital Management, L.P. (US$36.1M), TANG CAPITAL MANAGEMENT LLC (US$33.3M), IRIDIAN ASSET MANAGEMENT LLC/CT (US$16.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 NVCT 的基金
- Soleus Capital Management, L.P. 1.71M 股 · $36.13M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 1.58M 股 · $33.33M · Q3 2026
- IRIDIAN ASSET MANAGEMENT LLC/CT 793.21K 股 · $16.75M · Q3 2026
- Parkman Healthcare Partners LLC 425.35K 股 · $8.98M · Q3 2026
- BALDWIN WEALTH PARTNERS LLC/MA 382.01K 股 · $8.07M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 323.43K 股 · $6.83M · Q3 2026
- Occam Crest Management LP 2.80K 股 · $3.09M · Q3 2026
- Avidity Partners Management LP 100.42K 股 · $2.12M · Q3 2026
更多关于 BRAIDWELL LP
常见问题
How long has BRAIDWELL LP held NVCT?
BRAIDWELL LP has disclosed NVCT holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is BRAIDWELL LP's current position in NVCT?
As of Q3 2026, BRAIDWELL LP holds 1.57M shares of NVCT (NUVECTIS PHARMA INC), valued at $33.24M, representing 1.46% of its reported portfolio and ranking #24.
Has BRAIDWELL LP been buying or selling NVCT?
In the latest 13F filing (Q3 2026), BRAIDWELL LP newly opened its position in NVCT.
Which other funds hold NVCT?
Other major institutional holders of NVCT include Soleus Capital Management, L.P., TANG CAPITAL MANAGEMENT LLC, IRIDIAN ASSET MANAGEMENT LLC/CT, among 62 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.